New ELISA for B cell-activating factor

Area of Science:

• Immunology
• Biochemistry

Background:

• B cell-activating factor (BAFF) is implicated in autoimmune diseases.
• Existing ELISA methods for BAFF quantification show unreliable results.
• There is a need for a dependable BAFF measurement assay.

Purpose of the Study:

• To develop and validate a novel ELISA for accurate BAFF measurement.
• To overcome limitations of current BAFF quantification protocols.

Main Methods:

• Purification of BAFF and use of glycosylated and nonglycosylated recombinant BAFF.
• Evaluation of monoclonal antibodies (mAbs) and polyclonal antibodies (pAbs) for BAFF detection.
• Optimization of antibody pairs for enhanced BAFF capture and detection.

Main Results:

• Polyclonal antibodies (pAbs) demonstrated superior performance over monoclonal antibodies (mAbs) as capture antibodies.
• The optimal assay utilized unconjugated goat pAb for capture and biotinylated goat pAb for detection.
• The developed ELISA was unaffected by rheumatoid factor.

Conclusions:

• The new ELISA provides a reliable method for BAFF quantification.
• This assay offers insights into variations in serum BAFF concentrations across studies.
• It serves as a valuable tool for disease management where BAFF indicates therapeutic response.